Table 2

Therapy at discharge and follow-up plan for hospitalised cohort

Total (%)Edmonton (%)Rural Alberta (%)Regina (%)P values
VTE (all combined)<0.0001*
 Parenteral AC alone185 (26.6)160 (29.4)6 (20.0)19 (15.8)
 Parenteral AC+warfarin145 (20.9)83 (15.2)4 (13.3)58 (48.3)
 Warfarin158 (22.7)138 (25.%)5 (16.7)15 (12.5)
 DOAC197 (28.3)154 (28.3)15 (50.0)28 (23.3)
  Rivaroxaban192 (97.5)151 (98.1)14 (93.3)27 (96.4)
  Dabigatran2 (1.0)01 (6.7)1 (3.6)
  Apixaban3 (1.5)3 (2.0)00
 Not documented10 (1.4)10 (1.8)00
PE and PE+DVT<0.0001*
 Parenteral AC alone146 (25.3)129 (28.0)5 (26.3)12 (12.4)
 Parenteral AC+warfarin129 (22.4)77 (16.7)1 (5.3)51 (52.6)
 Warfarin132 (22.9)119 (25.8)2 (10.5)11 (11.3)
 DOAC161 (28.0)127 (27.6)11 (57.9)23 (23.7)
  Rivaroxaban156 (96.9)124 (97.6)10 (90.9)22 (95.6)
  Dabigatran2 (1.2)01 (9.1)1 (4.4)
  Apixaban3 (1.9)3 (2.4)00
 Not documented8 (1.4)8 (1.7)00
DVT alone0.045*
 Parenteral AC alone39 (32.8)31 (36.5)1 (9.1)7 (30.4)
 Parenteral AC+warfarin16 (13.4)6 (7.1)3 (2.7)7 (30.4)
 Warfarin26 (21.8)19 (22.4)3 (27.3)4 (17.4)
 DOAC36 (30.3)27 (31.8)4 (36.4)5 (21.7)
  Rivaroxaban36 (100)27 (100)4 (100)5 (100)
  Dabigatran0000
  Apixaban0000
 Not documented2 (1.7)2 (2.4)00
Follow-up†
 Family doctor358 (51.5)276 (50.6)20 (66.7)62 (51.7)P=0.23
 VTE clinic202 (29.1)201 (36.9)1 (3.3)0P<0.001
 Specialist124 (17.8)58 (10.6)3 (10.0)63 (52.5)P<0.001
 Anticoagulation clinic34 (4.9)10 (1.8)024 (20.0)P<0.001
 Return to ED10 (1.4)8 (1.5)2 (6.7)0P=0.045
 Other101 (14.5)90 (16.5)6 (20.0)5 (4.2)
 Not documented41 (5.9)33 (6.1)2 (6.7)6 (5.0)
  • *P value compares therapies (categorised as parenteral anticoagulant alone, parenteral anticoagulant with warfarin, warfarin or a direct acting anticoagulant) used across the three settings.

  • †Not mutually exclusive.

  • AC, anticoagulant; DOAC, direct oral anticoagulant; DVT, deep vein thrombosis; ED, emergency department; PE, pulmonary embolism; VTE, venous thromboembolism.